Wall Street Drifts to a Mixed Close in Thin Trading Following a Holiday Pause
Stock indexes drifted to a mixed finish on Wall Street as some heavyweight technology and communications sector stocks offset gains elsewhere in the market
All Posts in "News Team"
American Battery Tech To Gross $10M From Direct Offering
American Battery Technology said on Thursday it had agreed to sell $10 million worth of stock to two institutional investors in an at-the-market offering.
Awaiting FDA review, Medtronic details study of adaptive neurostimulation in Parkinson’s disease
Medtronic is offering a peek into its ongoing, at-home trial of people with Parkinson’s disease being treated with adaptive deep brain stimulation, a technology that’s currently under review at the FDA.
GE HealthCare claims FDA clearance for amyloid imaging software in Alzheimer’s disease
GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density of amyloid plaque in the brains of people with Alzheimer’s disease.
Innovent links cytokine fusion protein to responses in colorectal cancer
Innovent Biologics has made the case that its checkpoint inhibitor-cytokine fusion protein has a future in colorectal cancer. A phase 1 trial that combined the drug candidate with Avastin reported a 21.9% response rate, including signs of efficacy in patients with liver metastases and prior immunotherapy use.
FDA scraps adcomm for Applied’s rare disease drug ahead of November decision
After pushing back the decision date for Applied Therapeutics’ metabolic disorder drug govorestat, the FDA has now decided that a planned advisory committee meeting won’t be required.
Inflammation-focused Upstream set to join growing trickle of biotech IPOs
The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an intention to go public.
NIH establishes pandemic preparedness network, plans up to $100M in yearly funding for work on new treatments and vaccines
With COVID-19 still spreading and mpox emerging as a public health emergency of international concern, the National Institutes of Health (NIH) is upping preparations for future pandemics.
Novo Nordisk bets $600M biobucks on NanoVation’s ability to take genetic medicines beyond the liver
Novo Nordisk is continuing its push into genetic medicines, agreeing to pay NanoVation Therapeutics up to $600 million to collaborate on up to seven programs built on technology for targeting cells outside the liver.
Capricor sells Europe rights to DMD therapy for $35M as FDA application approaches
Having already scooped up the U.S. rights to Capricor Therapeutics’ late-stage Duchenne muscular dystrophy (DMD) therapy, Japan’s Nippon Shinyaku has signed off on $35 million in cash and a stock purchase to secure the same deal in Europe.
Notable Labs files for bankruptcy, ending ambitions for Boehringer cancer drug
Topas says celiac candidate shines in phase 2a but keeps data under wraps for now
Pfizer taps Triana to discover molecular glues for cancer and beyond in deal potentially worth $1.5B
J&J, with adult approval in sight, posts adolescent myasthenia gravis data on $6.5B FcRn blocker
Jasper dials up dose after complete responses come and go quickly in hives trial
Novartis channels Gargamel, terminating midphase SMURF1 trial
Transgene’s viral cancer vaccine flunks midphase test—but subgroup signal spurs ongoing analysis
Lilly picks UK for first European Gateway Lab as part of $364M investment plan
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen